VIOLÊNCIA

E …,
2008

Andrew X Zhu, Olivier Rosmorduc, TR Evans, Paul J

Ross, Armando Santoro, Flair Jose Carrilho, Jordi dspace.uevora.pt
Citado por 4
Bruix Tudó, Shukui Qin, Paul J Thuluvath, Josep
Journal
Maria
Artigos of Clinical
Llovet
relacionados Oncology,
i Bayer, 2014,
Marie-Aude vol. 33,Markus
Leberre, num. 6, p.
559-566, 2014 Meinhardt, Yoon-Koo Kang
Jensen, Gerold
Do Abacaxi ao Zero Tudo é
Manual de Sobrevivência pa
PURPOSE:
Pokémon Economistas
GO:To compare the clinical outcomes of sorafenib plus
either erlotinib or placebo in patients with advanced
faça Paulo Ferreira
o hepatocellular carcinoma (HCC) in a multicenter,
multinational, randomized, phase III trial.
download Paulo Ferreira, 2010
grátis
noPATIENTS AND METHODS: Por que razão escolhemos um produto
celular
Patients with advanced HCC and underlying Child- outro, num supermercado? Por que ra
Android
Pugh class A cirrhosis, who were naive to systemic não fazer nada têm a ver com econom
outreatment (N = 720), were randomly assigned to que a elasticidade influencia o preço d
iPhone.
sorafenib plus either erlotinib (n = 362) or placebo (n um jogo de futebol? De uma forma lev
[online]
= 358). The primary end point was overall survival pretende-se abordar os princípios da d
Disponível
(OS). agentes económicos: a Microeconomia
em: por exemplo, o significado da muito fa
http://www.
RESULTS: expressão “Não há almoços grátis”.
techtudo.
Median OS was similar in the sorafenib plus erlotinib
com.
and sorafenib plus placebo groups (9.5 v 8.5 months,
br/tudo- Ver em dspace.uevora.p
respectively; hazard ratio [HR], 0.929; P = .408), as
sobre/pokemon-
was median time to progression (3.2 v 4.0 months,
go.respectively; HR, 1.135; P = .18). In the
html
sorafenib/erlotinib arm versus the sorafenib/placebo
C arm, the overall response rate trended higher (6.6% v
Fagundes
3.9%,- respectively; P = .102), whereas the disease
Acesso
control rate was significantly lower (43.9% v 52.5%,
em:
respectively; P = .021). The median durations of
fev,
treatment with sorafenib were 86 days in the
2017
sorafenib/erlotinib arm and 123 days in the
Artigos relacionados
sorafenib/placebo arm. In the sorafenib/erlotinib and
sorafenib/placebo
Citado por 2
arms, the rates of treatment-

Artigos relacionados

À
VENDA:
OBRAS
DE
: